OR WAIT null SECS
Recipharm’s addition of Kemwell’s Bengaluru, India facility expands its solid- and liquid-dosage capabilities.
Recipharm announced on Feb. 20, 2017 that it completed the acquisition of Kemwell’s pharmaceutical businesses located in Bengaluru, India. The acquisition extends Recipharm’s capabilities in India.
As part of the transaction, Recipharm also has a right of first negotiation to acquire Kemwell’s Indian biopharma business, which is not included in the transaction and will continue to be retained by the sellers.
The acquired business, Recipharm Pharmaservices Private Ltd, employs 1200 and offers development services and commercial manufacturing of solid, semi-solid, liquid, and topical products. The solid-dosage plant was commissioned in 2008 and has approvals from US FDA, European Union, and other regulatory bodies. The oral liquids production plant was commissioned in 2011 and features automated high throughput large volume manufacturing, mainly for the Indian subcontinent. The development business provides formulation development, small-scale manufacturing for clinical trials and analytical services.
The acquisition was announced in April 2016.